CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	4,633	4,972	3,183	5,799	10,818	3,362
Market Cap Growth	53.82%	56.24%	-45.12%	-46.39%	221.74%	126.76%
Enterprise Value	2,748	3,506	1,600	3,628	9,172	2,466
PE Ratio	-	-32.37	-4.89	15.36	-31.01	50.29
PS Ratio	17.05	13.40	2656.64	6.34	15045.33	11.61
PB Ratio	2.22	2.64	1.70	2.42	6.50	3.58
P/FCF Ratio	-32.85	-18.43	-5.97	12.68	-42.14	67.25
P/OCF Ratio	-34.32	-19.10	-6.42	10.76	-45.38	59.32
EV/Sales Ratio	10.12	9.44	1335.33	3.97	12756.39	8.52
EV/EBITDA Ratio	-18.37	-26.79	-2.55	9.13	-27.07	34.23
EV/EBIT Ratio	-16.70	-23.26	-2.46	9.56	-26.35	36.64
EV/FCF Ratio	-21.54	-12.99	-3.00	7.93	-35.73	49.33
Debt / Equity Ratio	0.11	0.13	0.13	0.09	0.04	0.06
Debt / EBITDA Ratio	-1.20	-1.82	-0.39	0.57	-0.18	0.73
Debt / FCF Ratio	-1.41	-0.88	-0.46	0.49	-0.24	1.05
Quick Ratio	17.81	17.51	15.09	19.99	18.11	16.62
Current Ratio	17.81	17.54	15.30	20.17	18.21	17.29
Asset Turnover	0.12	0.17	0	0.35	0.00	0.42
Return on Equity (ROE)	-11.60%	-8.40%	-31.90%	16.20%	-29.00%	11.70%
Return on Assets (ROA)	-9.70%	-7.00%	-26.90%	14.50%	-26.00%	9.60%
Return on Capital (ROIC)	-12.88%	-10.49%	-31.76%	14.16%	-20.54%	4.68%
Earnings Yield	-4.69%	-3.09%	-20.43%	6.51%	-3.22%	1.99%
FCF Yield	-3.59%	-5.43%	-16.74%	7.88%	-2.37%	1.49%
Buyback Yield / Dilution	-3.96%	-1.90%	3.29%	-21.90%	-15.84%	-18.70%
Total Shareholder Return	-3.96%	-1.90%	3.29%	-21.90%	-15.84%	-18.70%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).